A Phase 3 interventional study of Ad26.ZEBOV, MVA-BN-Filo vaccine in Ebola Virus Disease, sponsored by London School of Hygiene and Tropical Medicine. Status unknown at 1 site in Congo, The Democratic Republic of the. Open to participants aged 1 Year and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-23.
Sponsored by London School of Hygiene and Tropical Medicine · Phase 3, Interventional, and Prevention
A single arm, open-label, non-randomized, interventional phase 3 study to measure safety and effectiveness of a heterologous, two dose preventative vaccine (Ad26. ZEBOV, MVA-BN®-Filo) against Ebola Virus Disease.
Ebola Virus Disease (EVD) is an acute, systemic, febrile syndrome caused by Ebola viruses. EVD has a case fatality ranging from 30% to 90% and spreads by direct contact with body fluids of symptomatic patients.
During the 2013-16 Ebola outbreak in Guinea, a Phase 3 cluster-randomised ring-vaccination trial using single-dose rVSV-ZEBOV-GP investigational vaccine reported 100% efficacy in protection against EVD. In 2016, the WHO Strategic Advisory Group of Experts (SAGE) on Immunization recommended the rapid deployment of rVSV-ZEBOV-GP in case of an EVD outbreak under an Expanded Access (compassionate use) protocol, with informed consent and Good Clinical Practice (GCP) compliance.
A new EVD outbreak started in North Kivu and Ituri provinces in the Democratic Republic of Congo in July 2018. Despite extensive control measures, including vaccination with rVSV-ZEBOV-GP in active outbreak areas, the outbreak has continued and WHO declared the outbreak a Public Health Emergency of International Concern on 17 July 2019. The ongoing outbreak has prompted consideration of additional vaccine candidates that might assist in preventing the spread of this infection to currently unaffected communities.
This study will investigate population-level vaccination with a two-dose prophylactic vaccine against Ebola, the Ad26.ZEBOV, MVA-BN-Filo vaccine that has been extensively studied in 11 previous safety and immunogenicity trials. This will be done by offering vaccination first to communities that neighbour the outbreak area or that are located on transport routes from the edge of the outbreak area to major centres like Goma.
In this study, approximately 500,000 healthy adults and children will be given the two-dose candidate vaccine regimen VAC52150 that consists of two vaccines, Ad26.ZEBOV and MVA-BN®-Filo, administered at an interval of 56 days (-14 day +28 day). Safety will be assessed in a safety subset of 1000 individuals and a pregnancy subset of up to 500 pregnant women will be followed to delivery. The first 100 infants born to these pregnant participants will be given a clinical examination at 3 months post-delivery. The study will estimate vaccine coverage of dose 1 and dose 2 overall and in different target groups and will also examine the knowledge and perceptions of persons eligible for large-scale delivery of a preventative Ebola vaccine with a two-dose vaccine strategy. The effectiveness of the vaccination on EVD will be determined through a test-negative case control study. The target sample size for the primary effectiveness evaluation is 110 laboratory-confirmed EVD cases.
An exploratory objective is to assess the immune response at before the second dose and 21 days after the second dose (MVN-BN-Filo) in a subgroup of 50 adults and 50 children who receive dose 2 beyond the recommended 56-day interval.
914 studies on the registry are indexed under Virus Diseases; 110 are open to participants now.
This study's enrollment of 20,426 is above the median of 102 across 604 interventional studies indexed under Virus Diseases.
Browse Virus Diseases studies →London School of Hygiene and Tropical Medicine is the lead sponsor of 296 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The vaccine Ad26.ZEBOV (5x10\^10 viral particles (vp)) will be given as the first dose and the vaccine MVA-BN-Filo (1x10\^8 infectious units (Inf U)) will be given as the second dose 56 (-14 day +28 day) days later.
Biological: Ad26.ZEBOV, MVA-BN-Filo vaccine
Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®. MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV.
Numbers and odds of vaccination status in Ebola Virus Diseases cases and in EVD-negative controls.
Test negative case control study of 110 laboratory confirmed EVD cases matched to controls who test negative for EVD. Effectiveness is derived from the odds ratio for vaccination in cases compared to controls to calculate vaccine effectiveness.
Time frame: Through study completion, an average of 2 years.
Number and proportion of adults and children with solicited and unsolicited serious adverse events.
Data on SAEs within one month post-dose 2 that are considered related to vaccination with Ad26. ZEBOV, MVA-BN®-Filo vaccine in adults and children.
Time frame: From date of first vaccination to the one month post-dose 2 assessment of the last vaccinated participant.
Number and proportion of adults and children receiving dose 1.
Vaccine uptake
Time frame: From date of first vaccination up to month 12.
Number and proportion of adults and children receiving dose 2.
Vaccine coverage
Time frame: From date of first vaccination up to month 12.
Number of participants participating in in-depth interviews and focus group discussions
Focus group discussions and in-depth interviews on participant and community perceptions of the trial and on vaccine acceptability.
Time frame: Through to study completion at month 24.
Samples collected for immunogenicity subset at 2 time points
Level of immunoglobulin G binding antibodies at dose 2 and 21 days post-dose 2
Time frame: From date of dose 2 through to 21 days post-dose 2.
Plan to share: Yes — Individual level data (de-identified) that underlie results in a publication.
Supporting information: Study protocol, Sap, Icf
This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
London School of Hygiene and Tropical Medicine